A single center, randomized, double-blinded, placebo-controlled Phase 1 study to investigate the safety and tolerability of PH10 in healthy adult subjects
Latest Information Update: 28 May 2025
At a glance
- Drugs Itruvone (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors VistaGen Therapeutics
Most Recent Events
- 23 May 2025 According to a VistaGen Therapeutics media release, data from this study will be presented at the American Society of Clinical Psychopharmacology (ASCP) Conference in Scottsdale, Arizona from May 27-30, 2025.
- 09 Nov 2023 Status changed from active, no longer recruiting to completed, according to a VistaGen media release.
- 21 Jun 2023 Results of this study assessing the safety and tolerability, presented in a VistaGen Therapeutics media release.